Krystof V - Search Results

1

Evaluation of Novel Substituted Furopyridines as Inhibitors of Protein Kinases Related to Tau Pathology in Alzheimer´s Disease.

Schade N, Koch P, Ansideri F, Krystof V, Holzer M, Hilgeroth A. Schade N, et al. Among authors: krystof v. Med Chem. 2021;17(8):844-855. doi: 10.2174/1573406417666210601144510. Med Chem. 2021. PMID: 34061007

2

8-Azapurines as new inhibitors of cyclin-dependent kinases.

Havlicek L, Fuksova K, Krystof V, Orsag M, Vojtesek B, Strnad M. Havlicek L, et al. Among authors: krystof v. Bioorg Med Chem. 2005 Sep 15;13(18):5399-407. doi: 10.1016/j.bmc.2005.06.007. Bioorg Med Chem. 2005. PMID: 15993080

3

4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.

Krystof V, Cankar P, Frysová I, Slouka J, Kontopidis G, Dzubák P, Hajdúch M, Srovnal J, de Azevedo WF Jr, Orság M, Paprskárová M, Rolcík J, Látr A, Fischer PM, Strnad M. Krystof V, et al. J Med Chem. 2006 Nov 2;49(22):6500-9. doi: 10.1021/jm0605740. J Med Chem. 2006. PMID: 17064068

4

Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity.

Jorda R, Havlícek L, McNae IW, Walkinshaw MD, Voller J, Sturc A, Navrátilová J, Kuzma M, Mistrík M, Bártek J, Strnad M, Krystof V. Jorda R, et al. Among authors: krystof v. J Med Chem. 2011 Apr 28;54(8):2980-93. doi: 10.1021/jm200064p. Epub 2011 Apr 6. J Med Chem. 2011. PMID: 21417417

5

Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases.

Zatloukal M, Jorda R, Gucký T, Řezníčková E, Voller J, Pospíšil T, Malínková V, Adamcová H, Kryštof V, Strnad M. Zatloukal M, et al. Among authors: krystof v. Eur J Med Chem. 2013 Mar;61:61-72. doi: 10.1016/j.ejmech.2012.06.036. Epub 2012 Jun 23. Eur J Med Chem. 2013. PMID: 22770608

6

Synthesis and biological evaluation of guanidino analogues of roscovitine.

Dolečková I, Cesnek M, Dračinský M, Brynda J, Voller J, Janeba Z, Kryštof V. Dolečková I, et al. Among authors: krystof v. Eur J Med Chem. 2013 Apr;62:443-52. doi: 10.1016/j.ejmech.2013.01.021. Epub 2013 Jan 22. Eur J Med Chem. 2013. PMID: 23399722

7

A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors.

Gucký T, Jorda R, Zatloukal M, Bazgier V, Berka K, Řezníčková E, Béres T, Strnad M, Kryštof V. Gucký T, et al. Among authors: krystof v. J Med Chem. 2013 Aug 8;56(15):6234-47. doi: 10.1021/jm4006884. Epub 2013 Jul 24. J Med Chem. 2013. PMID: 23829517

8

Synthesis and kinase inhibitory activity of new sulfonamide derivatives of pyrazolo[4,3-e][1,2,4]triazines.

Mojzych M, Šubertová V, Bielawska A, Bielawski K, Bazgier V, Berka K, Gucký T, Fornal E, Kryštof V. Mojzych M, et al. Among authors: krystof v. Eur J Med Chem. 2014 May 6;78:217-24. doi: 10.1016/j.ejmech.2014.03.054. Epub 2014 Mar 18. Eur J Med Chem. 2014. PMID: 24681986

9

Novel arylazopyrazole inhibitors of cyclin-dependent kinases.

Jorda R, Schütznerová E, Cankař P, Brychtová V, Navrátilová J, Kryštof V. Jorda R, et al. Among authors: krystof v. Bioorg Med Chem. 2015 May 1;23(9):1975-81. doi: 10.1016/j.bmc.2015.03.025. Epub 2015 Mar 14. Bioorg Med Chem. 2015. PMID: 25835357

10

Potential Clinical Uses of CDK Inhibitors: Lessons from Synthetic Lethality Screens.

Vymětalová L, Kryštof V. Vymětalová L, et al. Among authors: krystof v. Med Res Rev. 2015 Nov;35(6):1156-74. doi: 10.1002/med.21354. Epub 2015 Jun 25. Med Res Rev. 2015. PMID: 26114963 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

165 results

Search Page

Filters